國立虎尾科技大學 |

Management of Muscle Invasive Bladder Cancer

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Management of Muscle Invasive Bladder Cancer/ by Sanchia S. Goonewardene, Karen Ventii, Amit Bahl, Raj Persad, Hanif Motiwala, David Albala.
作者:	Goonewardene, Sanchia S.
其他作者:	Albala, David.
面頁冊數:	XXXIX, 590 p. 37 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Oncology. -
電子資源:	https://doi.org/10.1007/978-3-030-57915-9
ISBN:	9783030579159

Management of Muscle Invasive Bladder Cancer
Goonewardene, Sanchia S.

Management of Muscle Invasive Bladder Cancer[electronic resource] /by Sanchia S. Goonewardene, Karen Ventii, Amit Bahl, Raj Persad, Hanif Motiwala, David Albala. - 1st ed. 2021. - XXXIX, 590 p. 37 illus. in color.online resource. - Management of Urology,2730-6380. - Management of Urology,.

1. Introduction to muscle invasive bladder cancer -- 2. Epidemiology and risk factors in muscle invasive bladder cancer -- 3. The molecular basis of muscle invasive bladder cancer -- 4. Histological variants in MIBC - squamous cell and squamous differentiation -- 5. Histological variants in muscle invasive bladder cancer – adenocarcinoma -- 6. Histological variants in muscle invasive bladder Cancer - sarcomatoid cancer -- 7. MIBC Carcinosarcoma -- 8. Muscle invasive bladder cancer- small cell -- 9. MIBC plasmacytoid -- 10. MIBC and micropapillary bladder cancer -- 11. MIBC bladder cancer assessment and diagnosis -- 12. A systematic review on blue light cystoscopy in bladder cancer diagnostics -- 13. A systematic review on the staging conundrum in bladder cancer -- 14. Current state of investigations and limitations in muscle invasive bladder cancer -- 15. Risk stratification in bladder cancer -- 16. Preventative measures for those with high risk MIBC -- 17. Bladder cancer risk post pelvic irradiation -- 18. A systematic review on bladder preservation strategies and MIBC -- 19. Partial cystectomy -- 20. Muscle invasive bladder cancer and neoadjuvant chemotherapy -- 21. Controversies in clinical effectiveness of neoadjuvant chemotherapy -- 22. Trimodal therapy in bladder cancer -- 23. Systematic review on trimodal therapy in bladder cancer -- 24. Trimodal therapy - a systematic review -- 25. Reviews related to trimodal therapy for MIBC -- 26. Radical cystectomy lap open robotic -- 27. Prostate sparing cystectomy - a systematic review -- 28. A systematic review on nerve sparing cystoprostatectomy -- 29. MIBC - orthotopic vs ileal conduit -- 30. MIBC - a systematic review on orthotopic neobladder vs. ileal conduit -- 31. MIBC and radical cystectomy in the elderly -- 32. MIBC radical radiotherapy -- 33. MIBC - quality of life with urinary diversion -- 34. Neoadjuvant chemotherapy for muscle invasive bladder cancer -- 35. Muscle invasive bladder cancer and the staging conundrum -- 36. Radical cystectomy outcomes -- 37. Muscle Invasive bladder cancer and neoadjuvant chemotherapy -- 38. Muscle invasive bladder cancer and the staging conundrum -- 39. Physical pre-habilitation prior to radical cystectomy -- 40. Exercise therapy pre surgery -- 41. Patient fitness for surgery -- 42. CPEX testing prior to major urological surgery -- 43. Cardio-pulmonary exercise testing and major urological surgery -- 44. Robotic radical cystectomy and enhanced recovery -- 45. The robotic approach to redo surgery -- 46. Robotic cystectomy and intracorporeal neobladder formation -- 47. Secondary pelvic malignancies and bladder cancer -- 48. Organ sparing cystectomy -- 49. Robotic radical cystectomy -- 50. Robotic cystectomy and intracorporeal stoma formation -- 51. Orthotopic neobladders vs. ileal conduits -- 52. The role of enhanced recovery in robotic cystectomy -- 53. Robotic radical cystectomy and lymph node dissection -- 54. Robotic cystectomy and sentinel node mapping -- 55. Robotic radical cystectomy and intracorporeal stoma formation -- 56. Lap vs open vs robotic cystectomy -- 57. A systematic review on obesity in bladder cancer -- 58. Systematic review results on obesity in bladder cancer -- 59. Reviews on BMI and bladder cancer -- 60. Survivorship Issues in muscle invasive bladder cancer -- 61. Muscle invasive bladder cancer and health related quality of life -- 62. Body image in bladder cancer -- 63. The rationale for neoadjuvant chemotherapy -- 64. Support for partners in bladder cancer.

This book provides a systematic review of the management and treatment of this disease. The concise and highly structured chapters feature essential background knowledge and commentary on recent advances within each step of a range of patient pathways. Management of Muscle Invasive Bladder Cancer provides a framework for patients’ care based on the research, as well as practically and clinically oriented guidelines. This book is relevant to trainees and practicing urologists and oncologists, in addition to medical professionals involved in the treatment of bladder cancer.

ISBN: 9783030579159

Standard No.: 10.1007/978-3-030-57915-9doiSubjects--Topical Terms:

593951
Oncology.

LC Class. No.: RC870-923.2

Dewey Class. No.: 616.6

Management of Muscle Invasive Bladder Cancer
LDR:05577nam a22004215i 4500 001 1052680
003 DE-He213
005 20210817195113.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030579159 $9 978-3-030-57915-9
024 7 $a 10.1007/978-3-030-57915-9 $2 doi
035 $a 978-3-030-57915-9
050 4 $a RC870-923.2
050 4 $a RC875-899.5
072 7 $a MJS $2 bicssc
072 7 $a MED088000 $2 bisacsh
072 7 $a MJS $2 thema
082 0 4 $a 616.6 $2 23
100 1 $a Goonewardene, Sanchia S. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1205221
245 1 0 $a Management of Muscle Invasive Bladder Cancer $h [electronic resource] / $c by Sanchia S. Goonewardene, Karen Ventii, Amit Bahl, Raj Persad, Hanif Motiwala, David Albala.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a XXXIX, 590 p. 37 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Management of Urology, $x 2730-6380
505 0 $a 1. Introduction to muscle invasive bladder cancer -- 2. Epidemiology and risk factors in muscle invasive bladder cancer -- 3. The molecular basis of muscle invasive bladder cancer -- 4. Histological variants in MIBC - squamous cell and squamous differentiation -- 5. Histological variants in muscle invasive bladder cancer – adenocarcinoma -- 6. Histological variants in muscle invasive bladder Cancer - sarcomatoid cancer -- 7. MIBC Carcinosarcoma -- 8. Muscle invasive bladder cancer- small cell -- 9. MIBC plasmacytoid -- 10. MIBC and micropapillary bladder cancer -- 11. MIBC bladder cancer assessment and diagnosis -- 12. A systematic review on blue light cystoscopy in bladder cancer diagnostics -- 13. A systematic review on the staging conundrum in bladder cancer -- 14. Current state of investigations and limitations in muscle invasive bladder cancer -- 15. Risk stratification in bladder cancer -- 16. Preventative measures for those with high risk MIBC -- 17. Bladder cancer risk post pelvic irradiation -- 18. A systematic review on bladder preservation strategies and MIBC -- 19. Partial cystectomy -- 20. Muscle invasive bladder cancer and neoadjuvant chemotherapy -- 21. Controversies in clinical effectiveness of neoadjuvant chemotherapy -- 22. Trimodal therapy in bladder cancer -- 23. Systematic review on trimodal therapy in bladder cancer -- 24. Trimodal therapy - a systematic review -- 25. Reviews related to trimodal therapy for MIBC -- 26. Radical cystectomy lap open robotic -- 27. Prostate sparing cystectomy - a systematic review -- 28. A systematic review on nerve sparing cystoprostatectomy -- 29. MIBC - orthotopic vs ileal conduit -- 30. MIBC - a systematic review on orthotopic neobladder vs. ileal conduit -- 31. MIBC and radical cystectomy in the elderly -- 32. MIBC radical radiotherapy -- 33. MIBC - quality of life with urinary diversion -- 34. Neoadjuvant chemotherapy for muscle invasive bladder cancer -- 35. Muscle invasive bladder cancer and the staging conundrum -- 36. Radical cystectomy outcomes -- 37. Muscle Invasive bladder cancer and neoadjuvant chemotherapy -- 38. Muscle invasive bladder cancer and the staging conundrum -- 39. Physical pre-habilitation prior to radical cystectomy -- 40. Exercise therapy pre surgery -- 41. Patient fitness for surgery -- 42. CPEX testing prior to major urological surgery -- 43. Cardio-pulmonary exercise testing and major urological surgery -- 44. Robotic radical cystectomy and enhanced recovery -- 45. The robotic approach to redo surgery -- 46. Robotic cystectomy and intracorporeal neobladder formation -- 47. Secondary pelvic malignancies and bladder cancer -- 48. Organ sparing cystectomy -- 49. Robotic radical cystectomy -- 50. Robotic cystectomy and intracorporeal stoma formation -- 51. Orthotopic neobladders vs. ileal conduits -- 52. The role of enhanced recovery in robotic cystectomy -- 53. Robotic radical cystectomy and lymph node dissection -- 54. Robotic cystectomy and sentinel node mapping -- 55. Robotic radical cystectomy and intracorporeal stoma formation -- 56. Lap vs open vs robotic cystectomy -- 57. A systematic review on obesity in bladder cancer -- 58. Systematic review results on obesity in bladder cancer -- 59. Reviews on BMI and bladder cancer -- 60. Survivorship Issues in muscle invasive bladder cancer -- 61. Muscle invasive bladder cancer and health related quality of life -- 62. Body image in bladder cancer -- 63. The rationale for neoadjuvant chemotherapy -- 64. Support for partners in bladder cancer.
520 $a This book provides a systematic review of the management and treatment of this disease. The concise and highly structured chapters feature essential background knowledge and commentary on recent advances within each step of a range of patient pathways. Management of Muscle Invasive Bladder Cancer provides a framework for patients’ care based on the research, as well as practically and clinically oriented guidelines. This book is relevant to trainees and practicing urologists and oncologists, in addition to medical professionals involved in the treatment of bladder cancer.
650 2 4 $a Oncology. $3 593951
650 0 $a Surgery. $3 644132
650 0 $a Oncology . $3 1253469
650 0 $a Urology. $3 645258
700 1 $a Albala, David. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1304442
700 1 $a Motiwala, Hanif. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1323447
700 1 $a Persad, Raj. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1205222
700 1 $a Bahl, Amit. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1357429
700 1 $a Ventii, Karen. $e editor. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1353389
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030579142
776 0 8 $i Printed edition: $z 9783030579166
776 0 8 $i Printed edition: $z 9783030579173
830 0 $a Management of Urology, $x 2730-6380 $3 1357430
856 4 0 $u https://doi.org/10.1007/978-3-030-57915-9
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)